Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

the first half of 2008. NGX-4010 has been granted orphan status and has received fast track designation from the U.S. Food and Drug Administration (FDA) for HIV-DSP.

Regulatory and Commercialization Plans for NGX-4010

NeurogesX remains on track to complete the filing of a marketing authorization application (MAA) in 2007 for European regulatory approval of NGX-4010, under the European Medicines Agency's centralized filing procedure. The Company intends to seek approval in the European Union for a broad indication of peripheral neuropathic pain, which includes PHN, HIV-DSP and painful diabetic neuropathy (PDN), among others. The Company expects to submit an NDA with the FDA in the second half of 2008 for both PHN and HIV- DSP.

The Company has retained exclusive worldwide commercialization rights for NGX-4010 and intends to establish a focused specialty sales force in the United States to address its target market of pain centers and physicians who treat PHN and HIV-DSP. NeurogesX intends to enter into commercial partnerships for marketing and distribution outside the United States.

Conference Call and Webcast Information

A conference call to review the results of the C117 trial will begin at 11:30 a.m. EDT (8:30 a.m. PDT) on September 4, 2007 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.

The conference call dial-in numbers are 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning September 4, 2007 at 2:30 p.m. EDT (11:30 a.m. PDT) and ending on September 19, 2007. The replay telephone number is 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 254382.

A live web cast of the call will also be available from the Investor Relations section on the Company's web site at ht
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... Aug. 29, 2014 Diseases largely eradicated in ... ago are returning. Measles was declared eliminated in 2000, ... as of August 15—the highest incidence in 20 years. ... department declared whooping cough a problem of "epidemic ... sick and dying from these preventable diseases—in part because ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... China, April 16, 2011 China Medical Equipment ... provider of ultrasound and MRI systems in China, ... portable ultrasound machine. The iuStar100 utilizes Samplify,s high-performance, ... SAM1600 analog to digital converter (ADC) to deliver ...
... Md., April 15, 2011 The U.S. Food and ... or in combination with methotrexate, for the treatment ... children ages 2 years and older. ... Still,s disease, is a rare, potentially life-threatening disorder ...
Cached Medicine Technology:United Imaging Healthcare Leverages Samplify's Analog Front-End Solutions to Deliver New Portable Ultrasound System with Superior Image Quality 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
(Date:9/2/2014)... Health structures explain nearly 20% of the non-adherence ... of a joint ESC-OECD study presented today at ... explained more than 80% of non-adherence. , Professor ... combines clinical data and health structure characteristics of ... the reasons some patients with heart failure do ...
(Date:9/2/2014)... Attorney Robert M. Higgins has been ... Year" for Medical Malpractice Law - Plaintiffs. Higgins ... has been selected for inclusion in The Best Lawyers in ... practice area and designated metropolitan area is honored as the ... received during the peer-review assessments. , The Best ...
(Date:9/2/2014)... AURO the enterprise Canadian Public ... expansion of its leadership team with the appointment of ... Liang joins AURO in conjunction with his current role ... with the operations, product management and engineering teams to ... well as ensuring effective internal and external controls are ...
(Date:9/1/2014)... Securityhunter has experienced rapid growth ... search for a new, larger headquarters. The newly ... the space of our office to 10,000 square feet. ... from glass topped cubicles with doors, to beautiful large conference ... warehouse," says Michael S. Rogers, CEO of Securityhunter. “Our ...
Breaking Medicine News(10 mins):Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3Health News:Securityhunter, Inc. Announces the Relocation of Its Corporate Headquarters in Baltimore 2
... in ovarian cancer has provided the most comprehensive and integrated ... Ovarian serous adenocarcinoma tumors from 500 patients were examined by ... reported in the June 30, 2011, issue of Nature ... of ovarian cancer, accounting for about 85 percent of all ...
... (HealthDay News) -- Obesity is a major risk factor ... women, a new study finds. It included more than ... smoked and were followed for 28 years. During that time, ... disease and 487 (27 percent) from cancer. Researchers found ...
... recent study accepted for publication in The Endocrine Society,s ... early, prolonged treatment with the diabetes drug metformin may prevent ... adolescence. PCOS affects 7 to 10 percent of ... of infertility, affecting an estimated 5 to 6 million women ...
... Reporter , TUESDAY, June 28 (HealthDay News) -- A vaccine ... some promise, while another designed to alter insulin production fails, ... results of both studies were slated to be presented Tuesday ... Type 1 diabetes often appears early in life and ...
... are teaming up to offer one of the nation,s ... trucks. Led by the University of Maryland and ... program will target the so-called short-haul "drayage" fleet that ... The effort seeks to double the impact ...
... TUESDAY, June 28 (HealthDay News) -- Mammography screening reduces breast ... according to a new, large-scale Swedish trial. In a ... longest ever -- the researchers found that the benefits of ... In fact, most of the benefits occur more than 10 ...
Cached Medicine News:Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 2Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 3Health News:Obesity a Major Cause of Early Death in Women: Study 2Health News:Diabetes drug may prevent or delay development of polycystic ovary syndrome 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 3Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 2Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 3Health News:Longest Trial Ever Confirms Mammograms' Benefits 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: